Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 8.1% on Analyst Downgrade

Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) shares were down 8.1% during mid-day trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma traded as low as $27.04 and last traded at $27.36. 28,822 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 340,475 shares. The stock had previously closed at $29.76.

A number of other brokerages also recently commented on AVLN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Raymond James Financial began coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Wall Street Zen upgraded shares of Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avalyn Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.20.

Check Out Our Latest Analysis on AVLN

Insider Buying and Selling at Avalyn Pharma

In other news, insider Fmr Llc sold 175,000 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00. Following the completion of the transaction, the insider directly owned 2,109,535 shares in the company, valued at approximately $61,324,182.45. This represents a 7.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Avalyn Pharma during the third quarter worth about $29,000. Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma during the third quarter worth about $36,000. Profund Advisors LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at approximately $668,000. Bank of New York Mellon Corp purchased a new position in shares of Avalyn Pharma in the second quarter valued at approximately $1,321,000. Finally, State Street Corp purchased a new position in shares of Avalyn Pharma in the second quarter valued at approximately $10,501,000.

Avalyn Pharma Stock Down 7.2%

The company’s fifty day moving average is $28.51. The firm has a market cap of $1.22 billion and a PE ratio of -1.21. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). As a group, sell-side analysts expect that Avalyn Pharma Inc. will post -3.83 earnings per share for the current year.

Avalyn Pharma Company Profile

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.

Further Reading

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.